Comparison of daclatasvir and asunaprevir for chronic hcv 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma

Oncology (Switzerland)

Volumn 89, Issue , 2015, Pages 42-46

  Sugimoto, Kayo ^a,b   Kim, Soo Ryang ^b   Kim, Soo Ki ^b   Imoto, Susumu ^b   Tohyama, Madoka ^b   Kim, Ke Ih ^b   Ohtani, Aya ^b   Hatae, Takashi ^c   Yano, Yoshihiko ^a   Kudo, Masatoshi ^d   Hayashi, Yoshitake ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE ASAHI HOSPITAL   (Japan)

^c KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asunaprevir; Daclatasvir; Direct Acting antivirals; Hepatocellular carcinoma; Interferon free treatment; Occurrence; Prevention; Recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASUNAPREVIR; DACLATASVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; SULFONAMIDE; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CHRONIC HEPATITIS C; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET COUNT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; JAPAN; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; PREVENTION AND CONTROL; PROGNOSIS; TUMOR RECURRENCE; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; ISOQUINOLINES; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SIMEPREVIR; SULFONAMIDES; VIRAL LOAD;

EID: 84965093175     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000440630     Document Type: Article

References (26)

1. Kumada H, Suzuki Y, Ikeda K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-2091.
2. Poordad F, McCone J Jr, Bacon BR, et al: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. Hepatol Res 2014; 44(suppl S1):59-70.
5. Asahina Y, Tsuchiya K, Tamaki N, et al: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
6. Imai Y, Kawata S, Tamura S, et al: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-99.
7. Ikeda K, Saitoh S, Arase Y, et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-Term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.
8. Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
9. Bruno S, Stroffolini T, Colombo M, et al: Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-587.
10. Asahina Y, Tsuchiya K, Nishimura T, et al: Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-1262.
11. Kubo S, Takemura S, Sakata C, et al: Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer 2013; 2: 40-46.
12. Kudo M: Prediction of hepatocellular carcinoma incidence risk by ultrasound elastography. Liver Cancer 2014; 3: 1-5.
13. Mise Y, Sakamoto Y, Ishizawa T, et al: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013; 2: 55-66.
14. Kokudo N: Recent progress in the treatment and diagnosis of hepatocellular carcinoma. Liver Cancer 2013; 2: 4.
15. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013; 2: 73-83.
16. Chan SC, Sharr WW, Chan AC, et al: Rescue living-donor liver transplantation for liver failure following hepatectomy for hepatocellular carcinoma. Liver Cancer 2013; 2: 332-337.
17. Chan SC: Liver transplantation for hepatocellular carcinoma. Liver Cancer 2013; 2: 338-344.
18. Akamatsu N, Sugawara Y, Kokudo N: Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014; 3: 108-118.
19. Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-Alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
20. Chung H, Ueda T, Kudo M: Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
21. Thein HH, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-Analysis and meta-regression. Hepatology 2008; 48: 418-431.
22. Tanaka J, Kumagai J, Katayama K, et al: Sexand age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-Time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
23. Mizokami M, Tanaka Y, Miyakawa Y: Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. Intervirology 2006; 49: 28-36.
24. Huang CF, Yang JF, Dai CY, et al: Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751-759.
25. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801.
26. Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.